IMPROVING LIFE THROUGH BIOSCIENCE
Chairman & President
Vasilis has worked at and consulted for a number of pharmaceutical and biotech companies globally. Due to his innovation he has been the founder and director of seven biotech companies since 2000. In early 2006, he founded Adistem, Ltd in Hong Kong. After finishing his doctorate in pharmacology/endocrinology in 1993 at St Vincent’s Institute of Medical Research at the University of Melbourne, he completed his post-doctoral fellowship at Pfizer Central Research in Connecticut. During this time he was given two scholarships from the Australian Federal Government, and the National Health and Medical research Council of Australia and two young investigators awards in osteoporosis research from the Australian and New Zealand Bone and Mineral Society, and the International Society for Bone and Mineral Research. After doing his clinical training in Greece, he worked in combat trauma medicine in Africa where he stayed and did humanitarian work in Angola. In 2008, Dr. Paspaliaris received an Appreciation Award from the American Association of Clinical Endocrinologists for his groundbreaking work on adipose-derived stem cells in Type II diabetes and two certificates of appreciation from the American Academy of Anti-Aging Medicine on his stem cell research and an investigators award from the Hellenic Thoracic Society. Dr. Paspaliaris has published over 20 papers, holds over 5 patents and given lectures in a variety of medical fields, mostly in stem cell medicine. He is currently a Faculty Member for the Masters degree program in Clinical Pharmacology and Therapeutics at Democritus University Medical School and the University of Crete in Greece. He is a member of the World Society of Interdisciplinary Anti-aging Medicine, the Australian Military Medicine Association and Latin American Stem Cell Society, a Fellow of the Philippine Society of Stem Cell Medicine, a Diplomat of the American Board of Regenerative Medicine, a Fellow of the American Academy of Regenerative Medicine and a Fellow of the Royal Society of Medicine (UK).
Chief Executive Officer
Greg has over 40 years experience in the healthcare provider system working for providers of Care and Information Technology and Services companies in roles such as consulting, marketing, investor relations and new business development, working in both the Public and Private Health Sector, and performing a number of roles as both the vendor, client representative and industry consultant.
His roles include leading marketing, communications and investor relation’s functions in numerous early start health technology companies through to working for a health technology company for over 5 years which was dual-listed on the UK and Australian stock exchange with a market capitalization of over 1/2 billion dollars.
Greg has worked in Australia, New Zealand, South Africa, UK and the US and more recently SE Asia (and China) ranging from large multi-entity health delivery systems in Asia and China through to Private Hospitals in Australia, multi-entity hospital organisation in New Zealand, NSW Area Health Services, and a multi-entity payer based management solutions in the USA.
Across Asia and Greater China Greg has been involved in multiple company acquisitions, integration and subsequent board level and management of the acquired Asian companies.
Working together and alongside some of China’s largest telecommunications, internet, health media and healthcare organizations, Greg led a team from international software provider iSOFT developing and deploying health care services based on a converged service of video+social media over the internet and mobile devices.
Through this triple-play technology, this initiative entered a new era of home health care connecting the consumer in the community with their health professional and delivering healthcare knowledge via the consumer’s primary entertainment device.
Following the success of the China projects Greg went on to become divisional head of a international health technology supplier responsible for driving the companies technology and products into the areas of consumer health, pioneering internet technology, personal health records including new tools that would enable the clinician to truly deliver personalized healthcare.
Greg has consulted to, partnered with industry players and groups and established and driven his own initiatives in the areas of advance wellness, preventative care, and technology initiatives across the emerging Asian economies and traditional western world healthcare delivery systems.
In recent times Greg has been working in Asia developing and driving initiatives focused on preventative care and anti-aging strategies. From a startup position, Greg has been instrumental in driving strategy, marketing, and deployment of a high-end anti-aging facility located and integrated within an international 5-star hotel. This initiative required the development and deployment of a strategy based on regenerative, cutting-edge cell technology.
The project required Greg to lead a team of industry experts to develop a marketing, communications and delivery strategy that uses as its core enabler, stem cell technology whilst adopting both mainstream medicine and appropriate alternative and complementary techniques that consider the issues and treatment of regenerative, multi-factorial / multi-systemic chronic conditions that most doctors have great difficulty treating.
Greg strongly believes that with the arrival of cell-based technologies the stance shifts from curing the source of the problem at its core instead of removal of the symptoms, creating a new paradigm for regenerative, rejuvenating and preventative medicine. Greg’s passion in life.
Chief Operating Officer
Peter was educated in Melbourne, Australia, firstly at La Trobe University, where he completed a Bachelor Degree (Social Sciences) after undertaking studies across a diverse range of disciplines, including Science, Law and Arts, and later at Monash University, where he completed Pharmaceutical Industry specific Post Graduate (APMA CEP) qualifications. His career followed his passion, Health Care, and for the last 20 years he has worked in the Pharmaceutical Industry, developing extensive knowledge and experience in Sales, Marketing and Management across a number of therapeutic areas and medical sectors such as: Biotechnology, Cosmetic Medicine, Ophthalmology, Women’s Health, Surgical & Capital Equipment, Gastroenterology, CNS, Hospital, Aged Care and Pharmacy. From his early beginnings as a Sales Representative, on the front line, to Business Development, and National Sales & Marketing Management, all the way through to, Chief Operating Officer, and Director, Peter has a complete understanding, and perspective, of the intricate world of the Health Care and Pharmaceutical business. His expertise in this area has been acquired over 2 decades of working for some major Health Care/Pharmaceutical organisations in the industry including: WYETH AYERST and LEDERLE LABORATORIES, international pharmaceutical company, specialising in areas such as, Women’s health, Gastroenterology, Vaccine and CNS markets; ALCON LABORATORIES & SURGICAL, an international company specialising in the discovery, development, manufacture and marketing of surgical devices, vision care products and ophthalmic pharmaceuticals; and AUSTRALASIAN MEDICAL & SCIENTIFIC established with the aim of providing the Australian scientific and medical markets with a range of leading edge products from around the world. In the last two years Peter has been instrumental in the development of the business around the incorporated technologies into Adilyfe as he was working as the Business Development Manager of Adistem, General Manager of Paspa Pharmaceuticals, Director and Vice president of Black Arrow Biotech and Chief Operating Officer of Nereen Healthcare.
Chief Medical and Scientific Officer
George Kolios is Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece. He obtained his first degree in Medicine in 1980. In 1992, he obtained his PhD degree in Gastroenterology from the School of Medicine at the University of Athens, Greece and in 1998, his PhD degree in Pharmacology from the Department of Pharmacology at the University of Bath, United Kingdom. In 1990, he finished his Specialization in Gastroenterology and he first worked as Registrar in Gastroenterology at the Royal United Hospital, Bath, United Kingdom and then as Senior Registrar in the Gastroenterology Department at the Hippokration General Hospital, Athens, Greece. From 1998 till 2001, he worked as Consultant Gastroenterologist at the Royal United Hospital, Bath, and Senior Research Fellow in the Department of Pharmacology at the University of Bath, United Kingdom. In 2001, he was appointed Assistant Professor of Gastroenterology in the School of Medicine at the University of Crete and Visiting Professor in Pharmacology at the University of Bath, United Kingdom. From 2008 till today, he is a Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece and Director of the Master’s Degree Program “Clinical Pharmacology and Therapeutics” that is organized by the School of Medicine of Democritus University of Thrace. From 2008 till 2013, he was Member of the Scientific Board of Approvals of the Greek National Organization for Medicines. From 2013 till today, Professor Kolios is Vise-President of the School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Professor George Kolios is an experienced Clinical Gastroenterologist, and a very productive research scientist, with an extensive work in the area of immunopharmacology, mucosal immunology and fibrosis, mainly focused on the intestinal inflammation and Inflammatory Bowel Diseases. His work has demonstrated that the mucosal epithelium could be a rich source of various inflammatory mediators, including cytokines, chemokines and nitric oxide, which are involved in inflammation and fibrosis, and that these pro-inflammatory systems can be modified by cytokines derived by T-cell population. In addition, his work has been focused on the biology and the role of gut subepithelial myofibroblasts in fibrosis and on the interplay between gut mucosal immunity and microbiota. He has more than 80 papers in peer reviewed journals, which have been cited more than 3100 times with an h-index: 31.
Chief Legal Officer
Mr. David R. Strawn, over the past 38 years, has engaged in the practice of securities law, as an attorney, and has participated, as a private investor, in various business ventures. As a practicing attorney, Mr. Strawn has represented: registered broker dealers, venture capital investors, public reporting companies, issuers in private and IPO transactions, private and public companies in acquisition transactions, domestic broker-dealers and foreign broker-dealers engaged in cross boarder business and has participated in the development of an online Internet based trading system providing both order execution in trading securities and an online investment banking platform. Mr. Strawn has worked extensively in offshore financial markets and participated in the development of cross border PATRIOT Act compliance programs. As a private investor, Mr. Strawn has participated in the strategic planning, development and funding of start-up companies, and acquisition and collaboration transactions involving early stage growth and mid-cap companies engaged in various industries, including: mining and natural resources, healthcare, biosciences, financial services, telecommunication, construction and transportation. Mr. Strawn graduated from Portland State University, summa cum laude, with a degree in finance in 1977 and from the University of Arizona-Arizona School of Law, with honors, with a Juris Doctorate degree in 1980. Mr. Strawn resides in San Diego, California.
OUR MEDICAL AND SCIENTIFIC ADVISORY BOARD
Our Medical and Scientific Advisory Board is composed of pioneers in their respective fields of medicine and research, each contributing to our effort to develop and provide new and novel means to address human and animal suffering resulting from degenerative medical conditions.
Meet Members of our Medical and Scientific Advisory Board